VARIOUS measures have been proposed to reduce the endogenous production of oxalic acid in patients with primary hyperoxaluria; these include the oral administration of sodium benzoate, 1 pyridoxine, 2 ...
Genetic testing covered by companies that make treatments for primary hyperoxaluria can help identify cases of this rare condition, which often leads to kidney failure at an early age. These programs ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna TM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) therapies, today announced ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced preliminary ...
A DEFECT in the transamination of glyoxalate has been suggested as the metabolic abnormality responsible for the increased rate of oxalate synthesis in patients with primary hyperoxaluria (Fig. 1). 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback